Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Rev Soc Bras Med Trop ; 53: e20190560, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32348431

RESUMO

INTRODUCTION: Congenital transmission (CT) of Trypanosoma cruzi has led to globalization of Chagas disease and its growing relevance as a public health problem. Although the occurrence of CT has been associated with several factors, its mechanisms are still unknown. This study aimed to analyze the geographical and familiar variables of mothers and their association with CT of Chagas disease in a population living in non-endemic areas of Argentina for the last decades. METHODS: We developed a retrospective cohort study in a sample of 2120 mother-child pairs who attended three reference centers in the cities of Buenos Aires, Santa Fe, and Salta between 2002 and 2015. RESULTS: The highest CT rates were observed in children born to Argentinean mothers (10.7%) and in children born to mothers from Buenos Aires (11.7%). Considering the areas of origin of the mothers, those from areas of null-low risk for vector-borne infection had higher CT rates than those from areas of medium-high risk (11.1% vs 8.2%). We also observed a significant intra-familiar "cluster effect," with CT rates of 35.9% in children with an infected sibling, compared to 8.2% in children without infected siblings (RR=4.4 95% CI 2.3-8.4). CONCLUSIONS: The associations observed suggest a higher CT rate in children born to mothers who acquired the infection congenitally, with familiar antecedents, and from areas without the presence of vectors. These observations are considered new epidemiological evidence about Chagas disease in a contemporary urban population, which may contribute to the study of CT and may also be an interesting finding for healthcare professionals.


Assuntos
Doença de Chagas/epidemiologia , Doença de Chagas/transmissão , Transmissão Vertical de Doenças Infecciosas/estatística & dados numéricos , Complicações Parasitárias na Gravidez/epidemiologia , Adolescente , Adulto , Animais , Argentina/epidemiologia , Feminino , Humanos , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Gravidez , Estudos Retrospectivos , Fatores de Risco , População Urbana , Adulto Jovem
2.
Rev. Soc. Bras. Med. Trop ; 53: e20190560, 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1101445

RESUMO

Abstract INTRODUCTION: Congenital transmission (CT) of Trypanosoma cruzi has led to globalization of Chagas disease and its growing relevance as a public health problem. Although the occurrence of CT has been associated with several factors, its mechanisms are still unknown. This study aimed to analyze the geographical and familiar variables of mothers and their association with CT of Chagas disease in a population living in non-endemic areas of Argentina for the last decades. METHODS: We developed a retrospective cohort study in a sample of 2120 mother-child pairs who attended three reference centers in the cities of Buenos Aires, Santa Fe, and Salta between 2002 and 2015. RESULTS: The highest CT rates were observed in children born to Argentinean mothers (10.7%) and in children born to mothers from Buenos Aires (11.7%). Considering the areas of origin of the mothers, those from areas of null-low risk for vector-borne infection had higher CT rates than those from areas of medium-high risk (11.1% vs 8.2%). We also observed a significant intra-familiar "cluster effect," with CT rates of 35.9% in children with an infected sibling, compared to 8.2% in children without infected siblings (RR=4.4 95% CI 2.3-8.4). CONCLUSIONS: The associations observed suggest a higher CT rate in children born to mothers who acquired the infection congenitally, with familiar antecedents, and from areas without the presence of vectors. These observations are considered new epidemiological evidence about Chagas disease in a contemporary urban population, which may contribute to the study of CT and may also be an interesting finding for healthcare professionals.


Assuntos
Humanos , Animais , Masculino , Feminino , Gravidez , Recém-Nascido , Adolescente , Adulto , Adulto Jovem , Doença de Chagas/transmissão , Doença de Chagas/epidemiologia , Complicações Parasitárias na Gravidez/epidemiologia , Transmissão Vertical de Doenças Infecciosas/estatística & dados numéricos , Argentina/epidemiologia , População Urbana , Estudos Retrospectivos , Fatores de Risco , Pessoa de Meia-Idade
3.
Mem Inst Oswaldo Cruz ; 110(3): 289-98, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25993503

RESUMO

Chagas disease or American trypanosomiasis is, together with geohelminths, the neglected disease that causes more loss of years of healthy life due to disability in Latin America. Chagas disease, as determined by the factors and determinants, shows that different contexts require different actions, preventing new cases or reducing the burden of disease. Control strategies must combine two general courses of action including prevention of transmission to prevent the occurrence of new cases (these measures are cost effective), as well as opportune diagnosis and treatment of infected individuals in order to prevent the clinical evolution of the disease and to allow them to recuperate their health. All actions should be implemented as fully as possible and with an integrated way, to maximise the impact. Chagas disease cannot be eradicated due because of the demonstrated existence of infected wild triatomines in permanent contact with domestic cycles and it contributes to the occurrence of at least few new cases. However, it is possible to interrupt the transmission of Trypanosoma cruzi in a large territory and to eliminate Chagas disease as a public health problem with a dramatic reduction of burden of the disease.


Assuntos
Doença de Chagas/prevenção & controle , Controle de Insetos , Insetos Vetores , América/epidemiologia , Animais , Doença de Chagas/epidemiologia , Doença de Chagas/transmissão , Humanos , Saúde Pública
4.
Mem. Inst. Oswaldo Cruz ; 110(3): 289-298, 05/2015. graf
Artigo em Inglês | LILACS | ID: lil-745977

RESUMO

Chagas disease or American trypanosomiasis is, together with geohelminths, the neglected disease that causes more loss of years of healthy life due to disability in Latin America. Chagas disease, as determined by the factors and determinants, shows that different contexts require different actions, preventing new cases or reducing the burden of disease. Control strategies must combine two general courses of action including prevention of transmission to prevent the occurrence of new cases (these measures are cost effective), as well as opportune diagnosis and treatment of infected individuals in order to prevent the clinical evolution of the disease and to allow them to recuperate their health. All actions should be implemented as fully as possible and with an integrated way, to maximise the impact. Chagas disease cannot be eradicated due because of the demonstrated existence of infected wild triatomines in permanent contact with domestic cycles and it contributes to the occurrence of at least few new cases. However, it is possible to interrupt the transmission of Trypanosoma cruzi in a large territory and to eliminate Chagas disease as a public health problem with a dramatic reduction of burden of the disease.


Assuntos
Animais , Humanos , Doença de Chagas/prevenção & controle , Controle de Insetos , Insetos Vetores , América/epidemiologia , Doença de Chagas/epidemiologia , Doença de Chagas/transmissão , Saúde Pública
5.
J Trop Med ; 2012: 292138, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22523499

RESUMO

This paper reviews the evidence supporting the use of etiological treatment for Chagas disease that has changed the standard of care for patients with Trypanosoma cruzi infection in the last decades. Implications of this evidence on different levels of prevention as well as gaps in current knowledge are also discussed. In this regard, etiological treatment has shown to be beneficial as an intervention for secondary prevention to successfully cure the infection or to delay, reduce, or prevent the progression to disease, and as primary disease prevention by breaking the chain of transmission. Timely diagnosis during initial stages would allow for the prescription of appropriate therapies mainly in the primary health care system thus improving chances for a better quality of life. Based on current evidence, etiological treatment has to be considered as an essential public health strategy useful to reduce disease burden and to eliminate Chagas disease altogether.

6.
Am J Trop Med Hyg ; 82(1): 55-9, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20064996

RESUMO

Chagas' disease, or American trypanosomiasis, is caused by the protozoan parasite Trypanasoma cruzi. It is estimated that 15,000 new cases of congenital T. cruzi transmission occur in the Americas each year. The aim of this study was to estimate the rate of congenital T. cruzi infection in infants born to infected women living in Ushuaia, Argentina, as well to assess a serologic test using Shed Acute Phase Antigen (SAPA) for a timely diagnosis of congenital infection. The rate of congenital infection among children in the study was 4.4% (3/68). Our results show that for infants younger than 30 days of age, matched blood samples from mother and infant were capable of identifying congenital transmission of infection using an enzyme-linked immunosorbent assay with SAPA. For infants older than 3 months, congenital infection could be ruled out using the same procedure.


Assuntos
Glicoproteínas/sangue , Neuraminidase/sangue , Trypanosoma cruzi/isolamento & purificação , Tripanossomíase/diagnóstico , Argentina , Transmissão de Doença Infecciosa , Diagnóstico Precoce , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Lactente , Recém-Nascido , Gravidez , Tripanossomíase/congênito , Tripanossomíase/parasitologia , Tripanossomíase/transmissão
7.
Rev Soc Bras Med Trop ; 42(5): 484-7, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19967227

RESUMO

The objective was to detect Trypanosoma cruzi infection in 32 children in Salta, Argentina, born to 16 chronically infected young women who were treated with benznidazole. Tests were performed to assess the efficacy of treatment after 14 years. At the end of the follow up, 87.5% of the women were non-reactive to EIA tests, 62.5% to IHA and 43.8% to IFA. 62.5% of the women were non-reactive according to two or three serological tests. No infected children were detected among the newborns of mothers treated before their pregnancy.


Assuntos
Anticorpos Antiprotozoários/sangue , Doença de Chagas/tratamento farmacológico , Nitroimidazóis/uso terapêutico , Complicações Parasitárias na Gravidez/tratamento farmacológico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/imunologia , Argentina , Doença de Chagas/prevenção & controle , Doença de Chagas/transmissão , Feminino , Seguimentos , Humanos , Recém-Nascido , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Gravidez
8.
Rev. Soc. Bras. Med. Trop ; 42(5): 484-487, Sept.-Oct. 2009. tab
Artigo em Inglês | LILACS | ID: lil-532502

RESUMO

The objective was to detect Trypanosoma cruzi infection in 32 children in Salta, Argentina, born to 16 chronically infected young women who were treated with benznidazole. Tests were performed to assess the efficacy of treatment after 14 years. At the end of the follow up, 87.5 percent of the women were non-reactive to EIA tests, 62.5 percent to IHA and 43.8 percent to IFA. 62.5 percent of the women were non-reactive according to two or three serological tests. No infected children were detected among the newborns of mothers treated before their pregnancy.


O objetivo foi detectar a infecção do Trypanosoma cruzi em 32 crianças nacidas de 16 jovens mulheres cronicamente infectadas e tratadas com benzinadol, em Salta, Argentina. Testes foram feitos para avaliar a eficácia após 14 anos do tratamento. Ao final do seguimento 87.5 por cento das mulheres foram não reativas ao EIA, 62.5 por cento ao IHA e 43.8 por cento ao IFA. 62.5 por cento das mulheres foram não reativas de acordo a 3 ou 2 testes serológicos. Nenhuma criança infectada foi detectada entre os recém-nascidos de mães tratadas antes da gravidez.


Assuntos
Feminino , Humanos , Recém-Nascido , Gravidez , Anticorpos Antiprotozoários/sangue , Doença de Chagas/tratamento farmacológico , Nitroimidazóis/uso terapêutico , Complicações Parasitárias na Gravidez/tratamento farmacológico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/imunologia , Argentina , Doença de Chagas/prevenção & controle , Doença de Chagas/transmissão , Seguimentos , Transmissão Vertical de Doenças Infecciosas/prevenção & controle
9.
Mem Inst Oswaldo Cruz ; 104 Suppl 1: 167-80, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19753472

RESUMO

The purpose of this review is to describe research findings regarding chronic Chagas disease in Argentina that have changed the standards of care for patients with Trypanosoma cruzi infection. Indirect techniques (serological tests) are still the main tools for the primary diagnosis of infection in the chronic phase, but polymerase chain reaction has been shown to be promising. The prognosis of patients with heart failure or advanced stages of chagasic cardiomyopathy is poor, but a timely diagnosis during the initial stages of the disease would allow for prescription of appropriate therapies to offer a better quality of life. Treatment of T. cruzi infection is beneficial as secondary prevention to successfully cure the infection or to delay, reduce or prevent the progression to disease and as primary disease prevention by breaking the chain of transmission. Current recommendations have placed the bulk of the diagnostic and treatment responsibility on the Primary Health Care System. Overall, the current research priorities with respect to Chagas disease should be targeted towards (i) the production of new drugs that would provide a shorter treatment course with fewer side effects; (ii) the development of new tools to confirm cure after a full course of treatment during the chronic phase and (iii) biomarkers to identify patients with a high risk of developing diseases.


Assuntos
Doença de Chagas/diagnóstico , Doença de Chagas/tratamento farmacológico , Tripanossomicidas/uso terapêutico , Argentina , Biomarcadores/sangue , Cardiomiopatia Chagásica/diagnóstico , Cardiomiopatia Chagásica/tratamento farmacológico , Cardiomiopatia Chagásica/mortalidade , Doença de Chagas/mortalidade , Doença Crônica , Progressão da Doença , Eletrocardiografia , Humanos , Reação em Cadeia da Polimerase , Prognóstico , Testes Sorológicos/métodos
10.
Mem. Inst. Oswaldo Cruz ; 104(supl.1): 167-180, July 2009. graf, tab
Artigo em Inglês | LILACS | ID: lil-520877

RESUMO

The purpose of this review is to describe research findings regarding chronic Chagas disease in Argentina that have changed the standards of care for patients with Trypanosoma cruzi infection. Indirect techniques (serological tests) are still the main tools for the primary diagnosis of infection in the chronic phase, but polymerase chain reaction has been shown to be promising. The prognosis of patients with heart failure or advanced stages of chagasic cardiomyopathy is poor, but a timely diagnosis during the initial stages of the disease would allow for prescription of appropriate therapies to offer a better quality of life. Treatment of T. cruzi infection is beneficial as secondary prevention to successfully cure the infection or to delay, reduce or prevent the progression to disease and as primary disease prevention by breaking the chain of transmission. Current recommendations have placed the bulk of the diagnostic and treatment responsibility on the Primary Health Care System. Overall, the current research priorities with respect to Chagas disease should be targeted towards (i) the production of new drugs that would provide a shorter treatment course with fewer side effects; (ii) the development of new tools to confirm cure after a full course of treatment during the chronic phase and (iii) biomarkers to identify patients with a high risk of developing diseases.


Assuntos
Humanos , Doença de Chagas/diagnóstico , Doença de Chagas/tratamento farmacológico , Tripanossomicidas/uso terapêutico , Argentina , Biomarcadores/sangue , Doença Crônica , Cardiomiopatia Chagásica/diagnóstico , Cardiomiopatia Chagásica/tratamento farmacológico , Cardiomiopatia Chagásica/mortalidade , Doença de Chagas/mortalidade , Progressão da Doença , Eletrocardiografia , Reação em Cadeia da Polimerase , Prognóstico , Testes Sorológicos/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA